TGFB1 and non-small cell lung carcinoma: Before evaluating the effect of erlotinib on the TGF-β1–induced EMT process, we investigated cell viability in NSCLC A549, H1299, normal lung epithelium CPAE, and normal lung fibroblast IMR90 cells.